L ike other aggressive malignancies, acute myeloid leukemia (AML) is commonly associated with genomic instability, resulting in drug resistance and disease progression. The current goal is to identify therapies that inhibit cancer growth as well as providing a long-lasting clinical response. Growth factor receptors and growth signaling pathways are frequently the target of activating mutations in AML and have led to the identification of small molecule kinase inhibitors, although these have had mixed clinical success. For example, activating mutations of the receptor tyrosine kinase FLT3 (fms-related tyrosine kinase-3) occur in approximately 30% of AML and confer a poor prognosis. 1 First generation FLT3 inhibitors, including midostaurin, and newer, more potent second generation FLT3 inhibitors such as quizartinib or sorafenib, can lead to improved disease outcome but do not provide a cure. 2, 3 Resistance to these multi-kinase inhibitors in AML patients often arises due to the development of secondary mutations within mutant FLT3 as well as other factors. 4 In a study of 13 patients with relapsed or chemo-refractory mutant FLT3-expressing AML treated with sorafenib, following an initial clinical response, the majority of the patients lost their response over time, despite continued inhibition of FLT3.
2 Drug resistance in this study was believed to be in part due to sorafenib selection of resistant leukemic cells bearing the D835 mutation in FLT3.
As limited clinical efficacy and drug resistance are common features of tyrosine kinase inhibitors, such as sorafenib, which target mutant FLT3-positive leukemia, current preclinical studies of FLT3 inhibitors often include combination treatment strategies that pair FLT3 inhibitors with other agents. One novel combination treatment approach consists of a small molecule inhibitor able to inhibit the association between HDM2 (human double minute 2) and p53. HDM2 is a protein that regulates the activity of the p53 tumor suppressor protein, a key regulator of apoptosis, which functions upstream in the apoptotic cascade by both indirectly and directly regulating Bcl-2 family proteins. In cells expressing wild-type (wt) p53, the HDM2 protein binds to p53 and blocks its activity. Thus, inhibition of the association between HDM2 and p53 activates p53 and causes apoptosis of cells expressing wt p53. Disease targets for which use of an HDM2 inhibitor makes intuitive sense include hematopoietic malignancies and renal cell carcinoma, as the majority of hematologic malignancies are characterized by wt p53, 5 and the incidence of p53 mutations in renal cell carcinoma has been reported to be only around 20%. 6 In this issue of the journal, Zauli et al. report the results of their investigation into the mechanism of synergy between sorafenib and nutlin-3, an inhibitor of the HDM2/p53 interaction, 7 against primary AML cells and cell lines characterized by wt p53, mutant p53, or deleted p53. It should be pointed out that oncogenic FLT3 was unlikely to have been a primary target of sorafenib in these experiments due to its efficacy in wt FLT3-expressing cells. Vatsyayan et al. have recently established that sorafenib and nutlin-3 also have a synergistic effect against renal cell carcinoma, further hinting at a yet to be identified target of sorafenib. 8 Additional targets of the multikinase inhibitor, sorafenib, include VEGFR-2, PDGFR, Raf, and c-Kit, 9 which may play an important role in this drug's efficacy in combination with nutlin-3. The use of sorafenib as a single agent has limitations in these diseases but the recent reports effectively demonstrate a novel approach for the development of a promising therapeutic strategy that relies on the combined use of multi-kinase inhibitors and inhibitors of HDM2.
The data from Vatsyayan et al. demonstrated synergy between sorafenib and nutlin-3 against renal cell carcinoma in terms of inhibition of cell viability, pro-apoptotic effects, reduction of renal cell carcinoma migration, and induction of p53 levels and activity. In renal cell carcinoma, sorafenib as a single agent activates p53, and the combination of nutlin-3 and sorafenib leads to an increase in the half-life of p53. In the study by Zauli et al., sorafenib and nutlin-3 were observed to have a synergistic effect in terms of induction of apoptosis and autophagy against each of a panel of AML cell lines expressing different combinations of either wt or mutant FLT3 or wt or mutant p53, as well as primary AML cells. Importantly, the cells that were most sensitive to the combination of sorafenib and nutlin-3 were those harboring mutant FLT3. This finding is of potential clinical importance in that while FLT3-ITD has been proposed to be an oncogenic driver as well as a valid therapeutic target in AML, 10 tyrosine kinase inhibitors, such as midostaurin, 11 as single agents generally induce transient decreases in peripheral blood blasts and partial responses in patients harboring mutant FLT3. 3 Due to their limited therapeutic efficacy, it is common for FLT3 inhibitors in clinical development to be combined with standard chemotherapy, which is associated with unwanted adverse side effects/toxicity. The coupling of FLT3 inhibitors that have limited efficacy as single agents with targeted inhibitors of signaling molecules having an influence on the apoptotic machinery is an alternative approach to effective killing of mutant FLT3-positive cells, while also potentially circumventing the toxicity resulting from commonly used AML therapeutics such as doxorubicin and cytarabine.
In the study by Zauli et al., the sorafenib and nutlin-3 combination was effective in promoting apoptosis and autophagy in leukemic cells regardless of their wt or deleted/mutated p53 status. The pro-apoptotic Bcl2 family member Bax was observed to contribute to the induction of apoptosis by sorafenib combined with nutlin-3 in AML cells characterized by wt p53, whereas the pro-apoptotic Bcl2 family member Bak contributed to drug combinationinduced apoptosis of AML cells characterized by deleted p53. It should be noted that, as in the study by Vatsyayan et al. in which high concentrations of sorafenib (up to 50 mM) and nutlin-3 (up to 20 mM) were administered, Zauli et al. used concentrations of sorafenib and nutlin-3 ranging from 3-10 mM. It cannot, therefore, be entirely excluded that additional drug targets contributed in part to the observed effects.
As a multi-kinase inhibitor, sorafinib may have a broad spectrum of application. Sorafenib was approved for the treatment of advanced renal cancer in 2005, and showed sufficient efficacy in hepatocellular carcinoma to warrant its approval for this indication in 2007. The drug is also in late stage clinical trials for non-responsive thyroid cancer, and in early clinical trials for recurrent glioblastoma. In this respect, sorafenib might be unique for its broad spectrum of potential targets that gives it some efficacy in a variety of cancers. Mutations in p53 have been reported to be frequent in poorly differentiated human thyroid carcinomas 12 and sporadic in glioblastomas. 13 Malignancies such as AML and renal cancer, in which the incidence of wt p53 is high, would be expected to show the best clinical response to a combination therapy regimen that includes sorafenib and an HDM2 inhibitor. Studies such as those by Zauli et 
